Compare CZWI & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | PYXS |
|---|---|---|
| Founded | 1938 | 2018 |
| Country | United States | United States |
| Employees | N/A | 56 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 172.2M |
| IPO Year | 2006 | 2021 |
| Metric | CZWI | PYXS |
|---|---|---|
| Price | $21.13 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 18.1K | ★ 490.4K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 8.96 | 3.03 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | $7,043.98 |
| P/E Ratio | $55.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.15 | $0.97 |
| 52 Week High | $22.62 | $5.55 |
| Indicator | CZWI | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 69.11 | 79.98 |
| Support Level | $20.26 | $1.28 |
| Resistance Level | $21.95 | $3.89 |
| Average True Range (ATR) | 0.56 | 0.22 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 69.94 | 98.25 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.